Targeting the murine serotonin transporter: Insights into human neurobiology

Nature Reviews Neuroscience

Volumn 9, Issue 2, 2008, Pages 85-96

  Murphy, Dennis L ^a   Lesch, Klaus Peter ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN TRANSPORTER;

AGILITY; ANXIETY; BEHAVIOR DISORDER; BODY TEMPERATURE; BONE STRENGTH; GENE EXPRESSION; GENETIC ASSOCIATION; LOCOMOTION; METABOLIC SYNDROME X; MUSCLE STRENGTH; NEUROBIOLOGY; NONHUMAN; OBESITY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SLEEP; SOMATOSENSORY CORTEX; STOMACH MOTILITY; STRESS;

ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; BRAIN DISEASES, METABOLIC; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MUTATION; PHENOTYPE; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

MURINAE; MUS;

EID: 38649099407     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn2284     Document Type: Review

References (131)

1. Lesch, K.-P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531 (1996). This paper provided the first demonstration that a functional-repeat length variation in the transcriptional control region of the SLC6A4 gene is associated with anxiety-, depression-, and aggression-related personality traits. The authors also suggest a hypothesis for the SERT-specific genetic susceptibility of affective illnesses and related disorders.
2. Hu, X. Z. et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessivecompulsive disorder. Am. J. Hum. Genet. 78, 815-826 (2006).
3. Lesch, K. P. & Murphy, D. L. in Membrane Transport Diseases: Molecular Basis of Inherited Transport Defects (eds Broer, S. & Wagner, C. A.) 349-364 (Kluwer Academic/Plenum, New York, 2003).
4. Murphy, D. L., Lerner, A., Rudnick, G. & Lesch, K. P. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4, 109-123 (2004).
5. Greenberg, B. D. et al. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am. J. Med. Genet. 96, 202-216 (2000).
6. Hu, X. Z. et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64, 783-792 (2007).
7. Anguelova, M., Benkelfat, C. & Turecki, G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol. Psychiatry 8, 646-653 (2003).
8. Sen, S., Burmeister, M. & Ghosh, D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxietyrelated personality traits. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127, 85-89 (2004).
9. Uher, R. & McGuffin, P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol. Psychiatry 14 Aug 2007 (doi:10.1038/sj.mp. 4002067).
10. Kilic, F., Murphy, D. L. & Rudnick, G. A human serotonin transporter mutation causes constitutive activation of transport activity. Mol. Pharmacol. 64, 440-446 (2003).
11. Prasad, H. C. et al. Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc. Natl Acad. Sci. USA 102, 11545-11550 (2005).
12. Sutcliffe, J. S. et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am. J. Hum. Genet. 77, 265-279 (2005).
13. Wendland, J. R., Martin, B. J., Kruse, M. R., Lesch, K.-P. & Murphy, D. L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol. Psychiatry 11, 224-226 (2006).
14. Ozaki, N. et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol. Psychiatry 8, 895 & 933-936 (2003). This paper and reference 10 identified a functional coding-region variation in the SLC6A4 gene that segregates with a complex serotonin-related phenotype in several families.
15. Wendland, J. R., Kruse, M. R., Cromer, K. C. & Murphy, D. L. A large case-control study of common functional SLC6A4 and BDNF variants in obsessivecompulsive disorder. Neuropsychopharmacology 32, 2543-2551 (2007).
16. Wendland, J. R. et al. A novel, putative gain-offunction haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum. Mol. Genet. 30 Nov 2007 (doi:10.1093/hmg/ddm343).
17. Bengel, D. et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53, 649-655 (1998). This study, which used SLC6A4-knockout mice, was the first to characterize the relationship between SERT-dependent alterations in brain serotonin homeostasis and behaviour.
18. Ansorge, M. S., Zhou, M., Lira, A., Hen, R. & Gingrich, J. A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306, 879-881 (2004). This work provided evidence that transient pharmacological inhibition of SERT during early development produced abnormal emotional behaviours in adult mice and thus mimicked the behavioural phenotype of Slc6a4-mutant mice. The results suggest that a developmental mechanism explains how low SERT function increases vulnerability to psychiatric disorders.
19. Thakker, D. R. et al. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol. Psychiatry 10, 782-789 (2005).
20. Zhao, S. et al. Insertion mutation at the C-terminus of the serotonin transporter disrupts brain serotonin function and emotion-related behaviors in mice. Neuroscience 140, 321-334 (2006).
21. Jennings, K. A. et al. Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J. Neurosci. 26, 8955-8964 (2006).
22. Kendler, K. S., Kuhn, J. W., Vittum, J., Prescott, C. A. & Riley, B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch. Gen. Psychiatry 62, 529-535 (2005).
23. Holmes, A., Li, Q., Murphy, D. L., Gold, E. & Crawley, J. N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav. 2, 365-380 (2003).
24. Holmes, A., Yang, R. J., Lesch, K. P., Crawley, J. N. & Murphy, D. L. Mice lacking the serotonin transporter exhibit 5-HT1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28, 2077-2088 (2003).
25. Lira, A. et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter- deficient mice. Biol. Psychiatry 54, 960-971 (2003).
26. Kalueff, A. V., Ren-Patterson, R. F. & Murphy, D. L. The developing use of heterozygous mutant mouse models in brain monoamine transporter research. Trends Pharmacol. Sci. 28,122-127 (2007).
27. Carroll, J. C. et al. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav. Genet. 37, 214-222 (2007).
28. Adamec, R., Burton, P., Blundell, J., Murphy, D. L. & Holmes, A. Vulnerability to mild predator stress in serotonin transporter knockout mice. Behav. Brain Res. 170, 126-140 (2006).
29. Carola, V. et al. Identifying molecular substrates in a mouse model of the 5-HTT x environment risk factor for anxiety and depression. Biol. Psychiatry 17 Oct 2007 (doi: 10.1016/j.biopsych.2007.08.013).
30. Wellman, C. L. et al. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 27, 684-691 (2007).
31. Maciag, D. et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31, 47-57 (2006).
32. Mamounas, L. A. et al. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J. Neurosci. 20, 771-782 (2000).
33. Persico, A. M. et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J. Neurosci. 21, 6862-6873 (2001). This paper and reference 34 provided the first neuroanatomical demonstration of neurodevelopmental alterations in brain development as a function of SERT expression.
34. Salichon, N. et al. Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase A and 5-HT transporter knock-out mice. J. Neurosci. 21, 884-896 (2001).
35. Esaki, T. et al. Developmental disruption of serotonin transporter function impairs cerebral responses to whisker stimulation in mice. Proc. Natl Acad. Sci. USA 102, 5582-5587 (2005).
36. 1A) in 5-HT transporter knock-out mice: gender and brain region differences. J. Neurosci. 20, 7888-7895 (2000).
37. 1A binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291, 999-1007 (1999).
38. 2C receptors in serotonin transporter knockout mice. J. Neurochem. 84, 1256-1265 (2003).
39. Murphy, D. L. et al. Genetic perspectives on the serotonin transporter. Brain Res. Bull. 56, 487-494 (2001).
40. Ren-Patterson, R. F. et al. Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cell. Mol. Neurobiol. 26, 775-780 (2006).
41. Li, Q. Cellular and molecular alterations in mice with deficient and reduced serotonin transporters. Mol. Neurobiol. 34, 51-66 (2006).
42. Lanfumey, L., Mannoury La Cour, C., Froger, N. & Hamon, M. 5-HT-HPA interactions in two models of transgenic mice relevant to major depression. Neurochem. Res. 25, 1199-1206 (2000).
43. Tjurmina, O. A., Armando, I., Saavedra, J. M., Goldstein, D. S. & Murphy, D. L. Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 143, 4520-4526 (2002).
44. Tjurmina, O. A., Armando, I., Saavedra, J. M., Li, Q. & Murphy, D. L. Life-long serotonin reuptake deficiency results in complex alterations in adrenomedullary responses to stress. Ann. NY Acad. Sci. 1018, 99-104 (2004).
45. Armando, I., Tjurmina, O. A., Li, Q., Murphy, D. L. & Saavedra, J. M. The serotonin transporter is required for stress-evoked increases in adrenal catecholamine synthesis and angiotensin II AT2 receptor expression. Neuroendocrinology 78, 217-225 (2003).
46. Holmes, A., Murphy, D. L. & Crawley, J. N. Reduced aggression in mice lacking the serotonin transporter. Psychopharmacology (Berl.) 161, 160-167 (2002).
47. Kalueff, A. V., Wheaton, M. & Murphy, D. L. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav. Brain Res. 179,1-18 (2007).
48. Murphy, D. L. et al. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav. 2, 350-364 (2003).
49. Ren-Patterson, R. F. et al. Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. J. Neurosci. Res. 79, 756-771 (2005).
50. Wisor, J. P. et al. Altered rapid eye movement sleep timing in serotonin transporter knockout mice. Neuroreport 14, 233-238 (2003).
51. Fox, M. A. et al. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology 195, 147-166 (2007).
52. 1A sequences. J. Neurosci. 24, 10868-10877 (2004).
53. Chen, J. J. et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21, 6348-6361 (2001).
54. 7 serotonin receptors: a possible model and mechanism for differential human vulnerability to the serotonin syndrome. American College of Neuropsychopharmacology Annual Meeting (Abstr.) 60, S221-S222 (2006).
55. Vogel, C. et al. Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J. Neurosci. 23, 708-715 (2003). This study carried out a systematic assessment of pain sensitivity in Slc6a4-mutant mice.
56. Cornelissen, L. L., Brooks, D. P. & Wibberley, A. Female, but not male, serotonin reuptake transporter (5-HTT) knockout mice exhibit bladder instability. Auton. Neurosci. 122, 107-110 (2005).
57. Eddahibi, S. et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105, 1555-1562 (2000).
58. -/- mice.
59. Mekontso-Dessap, A. et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 81-89 (2006).
60. Warden, S. J., Bliziotes, M. M., Wiren, K. M., Eshleman, A. J. & Turner, C. H. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol. Cell Endocrinol. 242, 1-9 (2005).
61. Bliziotes, M., Gunness, M., Eshleman, A. & Wiren, K. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J. Musculoskelet. Neuronal Interact. 2, 291-295 (2002).
62. Holmes, A. et al. Adult-onset obesity and neurovegetative abnormalities in serotonin transporter null mutant mice. American College of Neuropsychopharmacology (Abstr.) 29904 (2002).
63. Diem, S. J. et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167, 1240-1245 (2007).
64. Haney, E. M. et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167, 1246-1251 (2007).
65. Warden, S. J., Robling, A. G., Sanders, M. S., Bliziotes, M. M. & Turner, C. H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146, 685-693 (2005).
66. Sora, I. et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl Acad. Sci. USA 98, 5300-5305 (2001).
67. Tecott, L. H. et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374, 542-546 (1995).
68. 1B receptor knockout mice have higher body weights than wildtypes. Physiol. Behav. 74, 507-516 (2001).
69. Gobbi, G., Murphy, D. L., Lesch, K.-P. & Blier, P. Modifications of the serotoninergic system in mice lacking serotonin transporters. An in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296, 987-995 (2001).
70. 2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berl.) 180, 12-20 (2005).
71. Kelai, S. et al. Alcohol intake after serotonin transporter inactivation in mice. Alcohol Alcohol. 38, 386-389 (2003).
72. Trigo, J. M. et al. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry 62, 669-679 (2007).
73. Montanez, S., Owens, W. A., Gould, G. G., Murphy, D. L. & Daws, L. C. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J. Neurochem. 86, 210-219 (2003).
74. Boyce-Rustay, J. M. et al. Ethanol-related behaviors in serotonin transporter knockout mice. Alcohol Clin. Exp. Res. 30, 1957-1965 (2006).
75. Sora, I. et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl Acad. Sci. USA 95, 7699-7704 (1998). This paper, together with reference 66, used double-knockout mice to provide the first evidence that cocaine reward and dependence is mediated by both the dopamine transporter and SERT.
76. Fox, M. A., Huang, S.-J., Tolliver, T. J. & Murphy, D.L. Enhanced increases in serotonin underlie exaggerated serotonin syndrome behaviors in serotonin transporter (SERT) knockout mice. Neuropsychopharmacology (in the press).
77. Fox, M. A., Jensen, C. L., Gallagher, P. S. & Murphy, D. L. Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology 53, 643-656 (2007).
78. Gershon, M. D., Payette, R. F. & Rothman, T. P. Development of the enteric nervous system. Fed. Proc. 42, 1620-1625 (1983).
79. Gershon, M. D., Chalazonitis, A. & Rothman, T. P. From neural crest to bowel: development of the enteric nervous system. J. Neurobiol. 24, 199-214 (1993).
80. Gaspar, P., Cases, O. & Maroteaux, L. The developmental role of serotonin: news from mouse molecular genetics. Nature Rev. Neurosci. 4, 1002-1012 (2003). This paper provides a comprehensive overview of the role of serotonin in the modulation of different developmental processes, such as neurogenesis, apoptosis, axon branching and dendritogenesis.
81. McCaffery, J. M. et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom. Med. 68, 187-200 (2006).
82. Scherrer, J. F. et al. A twin study of depression symptoms, hypertension, and heart disease in middleaged men. Psychosom. Med. 65, 548-557 (2003).
83. Mathews, T. A. et al. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 140, 169-181 (2004).
84. Zhou, F. C., Lesch, K. P. & Murphy, D. L. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res. 942, 109-119 (2002).
85. Schmitt, A. et al. Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J. Neurosci. Res. 71, 701-709 (2003).
86. Lesch, K. P. & Mossner, R. Inactivation of 5HT transport in mice: modeling altered 5HT homeostasis implicated in emotional dysfunction, affective disorders, and somatic syndromes. Handb. Exp. Pharmacol., 417-456 (2006).
87. 1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci. 12, 2299-2310 (2000).
88. 1A autoreceptors in knockout mice deficient in the 5-HT transporter. Eur. J. Neurosci. 18, 2203-2212 (2003).
89. 2A receptors in mice lacking the serotonin transporter. Neurosci. Lett. 262, 113-116 (1999).
90. 2C receptors in the rat choroid plexus. Neuropsychopharmacology 15, 143-151 (1996).
91. Holmes, A., Yang, R. J., Murphy, D. L. & Crawley, J. N. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27, 914-923 (2002).
92. Lucki, I. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry 44, 151-162 (1998).
93. Weiger, W. A. Serotonergic modulation of behaviour: a phylogenetic overview. Biol. Rev. Camb. Philos. Soc. 72, 61-95 (1997).
94. Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152 (1999).
95. Cohen, Z., Bonvento, G., Lacombe, P. & Hamel, E. Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 50, 335-362 (1996).
96. Munafo, M. R., Clark, T. G., Roberts, K. H. & Johnstone, E. C. Neuroticism mediates the association of the serotonin transporter gene with lifetime major depression. Neuropsychobiology 53, 1-8 (2006).
97. Lesch, K. P. Alcohol dependence and gene x environment interaction in emotion regulation: is serotonin the link? Eur. J. Pharmacol. 526, 113-124 (2005).
98. Rausch, J. L. et al. Depressed patients have higher body temperature: 5-HT transporter long promoter region effects. Neuropsychobiology 47, 120-127 (2003).
99. Yeo, A. et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 53, 1452-1458 (2004).
100. Eddahibi, S. et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108, 1839-1844 (2003).
101. Caspi, A. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389 (2003). This paper, together with strong replications (references 9 and 22), proposed that the effect of SLC6A4-gene variation on depression risk in humans interacts with psychosocial stress. It also confirmed the findings in non-human-primate and rodent models of the existence of a neurodevelopmentally critical period of early postnatal life during which this interaction occurs.
102. Canli, T. et al. Neural correlates of epigenesis. Proc. Natl Acad. Sci. USA 103, 16033-16038 (2006). This study, together with reference 108, used highresolution functional MRI to demonstrate that serotonin transport efficiency is important for brain processes involving neural systems that control affective, cognitive and motor processes. The authors also showed that life stress differentially moderates the functional connectivity of the amygdala and hippocampus with a wide network of other brain regions in individuals with different SLC6A4 genotypes.
103. Nakatani, D. et al. Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am. Heart J. 150, 652-658 (2005).
104. Fumeron, F. et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de l'Infarctus du Myocarde (ECTIM). Circulation 105, 2943-2945 (2002).
105. Canli, T. & Lesch, K. P. Long story short: the serotonin transporter in emotion regulation and social cognition. Nature Neurosci. 10, 1103-1109 (2007). This paper contains a hypothesis that attempts to account for a role of SERT at the interface of emotionality and the social brain. The authors suggest that serotonergic signalling pathways integrate elementary tasks of sensory processing, cognition, emotion regulation and motor activity and posit that the potential impact on social cognition transcends the boundaries of behavioural genetics to embrace biosocial science and create a new social neurogenetics of behaviour.
106. Barr, C. S. et al. The utility of the non-human primate; model for studying gene by environment interactions in behavioral research. Genes Brain Behav. 2, 336-340 (2003).
107. Bennett, A. J. et al. Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol. Psychiatry 7, 118-122 (2002). By taking advantage of a non-human-primate maternal-separation paradigm, this paper provided the first evidence for a SLC6A4-gene-environment interaction that results in persistent alteration of brain serotonin function.
108. Canli, T. et al. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc. Natl Acad. Sci. USA 102, 12224-12229 (2005).
109. Shen, H. W. et al. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29, 1790-1799 (2004).
110. Bethea, C. L., Gundlah, C. & Mirkes, S. J. Ovarian steroid action in the serotonin neural system of macaques. Novartis Found. Symp. 230, 112-130 (2000).
111. Homberg, J. et al. Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system. Neuroscience 146, 1662-1676 (2007).
112. Homberg, J. R. et al. Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility. Eur. J. Neurosci. 26, 2066-2073 (2007).
113. Sakai, K. et al. Novel variants of murine serotonin transporter mRNA and the promoter activity of its upstream site. Neurosci. Lett. 342, 175-178 (2003).
114. Ozsarac, N., Santha, E. & Hoffman, B. J. Alternative non-coding exons support serotonin transporter mRNA expression in the brain and gut. J. Neurochem. 82, 336-344 (2002).
115. Buznikov, G. A., Peterson, R. E., Nikitina, L. A., Bezuglov, V. V. & Lauder, J. M. The pre-nervous serotonergic system of developing sea urchin embryos and larvae: pharmacologic and immunocytochemical evidence. Neurochem. Res. 30, 825-837 (2005).
116. +/Cl--dependent neurotransmitter transporters. Nature 437, 215-223 (2005).
117. Henry, L. K., Defelice, L. J. & Blakely, R. D. Getting the message across: a recent transporter structure shows the way. Neuron 49, 791-796 (2006). This paper contains a hypothesis based on data from reference 116 that helps explain the biochemical and mutagenesis studies performed with related mammalian neurotransmitter transporters. The authors suggest a model for how coupling arises between ions and substrates to permit efficient neurotransmitter clearance.
118. Aa template. Bioorg. Med. Chem. Lett. 16, 5594-5597 (2006).
119. Zhang, Y. W. & Rudnick, G. The cytoplasmic substrate permeation pathway of serotonin transporter. J. Biol. Chem. 281, 36213-36220 (2006).
120. Singh, S. K., Yamashita, A. & Gouaux, E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448, 952-956 (2007).
121. Saier, M. H. Jr. Tracing pathways of transport protein evolution. Mol. Microbiol. 48, 1145-1156 (2003).
122. Gage, P. J., Suh, H. & Camper, S. A. Dosage requirement of Pitx2 for development of multiple organs. Development 126, 4643-4651 (1999).
123. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-720 (1996).
124. Fisher, R. A. The Genetical Theory of Natural Selection (Oxford Univ. Press, Oxford, 1930).
125. Otto, S. P. Two steps forward, one step back: the pleiotropic effects of favoured alleles. Proc. Biol. Sci. 271, 705-714 (2004).
126. Gould, S. J. Is a new and general theory of evolution emerging? Paleobiology 6, 119-130 (1980).
127. Turner, J. R. G. Fisher's evolutionary faith and the challenge of mimicry. Oxf. Surv. Biol. 2, 159-196 (1985).
128. Huxley, J. Evolution, the Modern Synthesis (George Allen & Unwin, London, 1942).
129. Lande, R. The genetic covariance between characters maintained by pleiotropic mutations. Genetics 94, 203-215 (1980).
130. Fuxe, K. et al. Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 22, 389-400 (1983).
131. Hillarp, N. A., Fuxe, K. & Dahlstrom, A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol. Rev. 18, 727-741 (1966).